Xinyi Lin
NHC Key Laboratory Of Myopia And Related Eye Diseases, Shanghai Key Laboratory Of Visual Impairment And Restoration
Shanghai, 200031, China
Shanghai, 200031, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Submarine groundwater discharge governs dissolved carbon cycling: Multi-scale evidence from a large river-dominated groundwater-saltmarsh-estuary system.
Journal: Marine pollution bulletin
Published: April 01, 2025
Novel Eu3+-activated Ca3Ga2Ge4O14 red-emitting phosphors with high quantum efficiency for plant growth lighting and white LEDs.
Journal: Dalton transactions (Cambridge, England : 2003)
Published: October 01, 2024
TRPA1 exacerbates selective retinal ganglion cell vulnerability under acute ocular hypertension.
Journal: Acta neuropathologica communications
Published: September 16, 2024
A novel three-dimensional method for detailed analysis of RGC central projections under acute ocular hypertension.
Journal: Experimental eye research
Published: August 12, 2024
PD-1 blockade treatment in melanoma: Mechanism of response and tumor-intrinsic resistance.
Journal: Cancer science
Published: May 29, 2024
The Role of CDCA2 in tumor genesis, prognosis and future treatments.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 19, 2024
Novel Sm3+-doped La3Ga5MO14 (M = Si or Ge) phosphors for indoor illumination: effects of M cations on photoluminescence.
Journal: Dalton transactions (Cambridge, England : 2003)
Published: January 23, 2024
Pyroelectric catalytic performance of Sm3+-modified Pb(Mg1/3Nb2/3)O3-PbTiO3 for organic dyes: degradation efficiency, kinetics and pyroelectric catalytic mechanism.
Journal: Dalton transactions (Cambridge, England : 2003)
Published: October 05, 2023
Prediction of nonsentinel lymph node metastasis in acral melanoma with positive sentinel lymph nodes.
Journal: Journal of surgical oncology
Published: February 05, 2023
Correction to: BRAF Inhibitor Resistance in Meslanoma: Mechanisms and Alternative Therapeutic Strategies.
Journal: Current treatment options in oncology
Published: December 02, 2022
CDCA2 promotes melanoma progression by inhibiting ubiquitin-mediated degradation of Aurora kinase A.
CDCA2 promotes melanoma progression by inhibiting ubiquitin-mediated degradation of Aurora kinase A.
Journal: European journal of cancer (Oxford, England : 1990)
Published: September 29, 2022
Last Updated: 09/26/2026